<DOC>
	<DOC>NCT01499004</DOC>
	<brief_summary>This study will explore the drug behavior and safety following a single dose of three different 22 milligram tofacitinib (CP-690,550) modified-release formulations in 30 healthy volunteers. These formulations will be compared to 10 milligram tofacitinib (CP-690-550) in an immediate-release formulation.</brief_summary>
	<brief_title>A Phase 1 Study To Evaluate The Pharmacokinetics And Safety Of Three Modified Release And One Immediate Release Formulations Of Tofacitinib (CP-690,550) In Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Healthy male subjects and/or healthy females subjects who are of nonchildbearing potential. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease; Clinically significant infections within the past 3 months</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>tofacitinib</keyword>
	<keyword>CP-690</keyword>
	<keyword>550</keyword>
	<keyword>relative bioavailability</keyword>
	<keyword>modified release</keyword>
	<keyword>Phase 1</keyword>
</DOC>